TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01937104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60
Study: NCT03575403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will receive placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will receive duloxetine capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will receive duloxetine capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subjects will receive methylphenidate capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subjects will receive methylphenidate capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Subjects will receive methylphenidate capsules.
Study: NCT00979303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography and 3D navigational system
Description: Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
Study: NCT01807793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study: NCT04111263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FP
Description: Fiber and polyphenol blend

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High altitude
Description: Simulated high altitude in altitude chamber using hypobaric hypoxia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High altitude
Description: Simulated high altitude in altitude chamber using hypobaric hypoxia
Study: NCT04313725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tangible Boost
Description: Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
Study: NCT04111263

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sea level
Description: Sea level environment in altitude chamber
Study: NCT01878292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo tablets, once per day, oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone tablets, 15 mg per day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone tablets, 30 mg once per day, oral administration
Study: NCT00557752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
Study: NCT03934047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
Study: NCT02816788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine Assisted Therapy (EAT)
Description: Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
Study: NCT03644264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer carbonate
Description: sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
Study: NCT02997150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 Low dose
Description: Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection
Study: NCT03909945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Annona muricata
Description: Patients with prehypertension or stage 1 hypertension, in dietary measures, will received daily one tablet of 796 mg of aqueous extracts of Annona muricata leaves. During 60 days
Study: NCT02057458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil (Acute-1 hour)
Description: Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil (Acute-1 hour)
Description: Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil (Subchronic-4 weeks)
Description: Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill designed to mimic the sildenafil treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill designed to mimic the sildenafil treatment
Study: NCT06139666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Solution
Description: Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injectable Solution
Description: Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery.~The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count.
Study: NCT01937104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%
Study: NCT03079050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 MG
Description: This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
Study: NCT02634437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Study: NCT02436057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AEGIS (Automated Evaluation of Gastrointestinal Symptoms)
Study: NCT00913406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lutein fortification

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Study: NCT02992938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT02024646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered via subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via subcutaneous injection until week 24.
Study: NCT02004509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant
Description: Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
Study: NCT01458808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Description: Restriction of 2 grams on daily sodium diet intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration reduction
Description: Reduction of dialysate sodium concentration from 138 to 135 mEq/L
Study: NCT05174325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab + chemotherapy
Description: Biological : Sintilimab 100mg: 10ml Method of administration: 200mg IV D1 Q3W. Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W. Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.
Study: NCT03326180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 266mg/20ml vial of EXPAREL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: 100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: 100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
Study: NCT01510730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eradication treatment of Helicobacter pylori infection
Description: Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
Study: NCT02549092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Medical Treatment
Description: Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa-Carbidopa Intestinal Gel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube
Description: optional prior to PEG-J placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasojejunal (NJ) tube
Description: optional prior to PEG-J placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Study: NCT01390233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prepidil Gel
Description: Pre-induction cervical ripening using dinoprostone gel in the vagina.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Balloon Catheter
Description: Pre-induction cervical ripening using a urinary balloon catheter device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Urinary Catheter & Prepidil Gel
Description: Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
Study: NCT01633047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy exercises
Description: Control group that will be submitted only to physical therapy exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy exercises
Description: Control group that will be submitted only to physical therapy exercises
Study: NCT03537872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies
Description: In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Public Sector (PS) Health Facilities TB/HIV Integration Strategies
Description: STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
Study: NCT02407275

Intervention type: OTHER
Group type: OTHER
Intervention: Biological sample
Study: NCT03373162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
Study: NCT01357863

Intervention type: DRUG
Intervention: Treatment
Description: Patients treated with Lapatinib-capecitabine after Trastuzumab progression

Intervention type: DRUG
Intervention: Treatment
Description: Patients treated with Lapatinib-capecitabine after Trastuzumab progression
Study: NCT03821545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and Ketamine
Description: Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% NaCl)
Description: Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
Study: NCT00772941

Intervention type: DRUG
Intervention: Varenicline
Description: Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.~The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks.
Study: NCT05592873

Intervention type: DRUG
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Description: Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
Study: NCT01578512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face
Description: Face-to-Face behavioral weight loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based
Description: Web-based behavioral weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session
Description: The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
Study: NCT02976220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Education
Description: Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
Study: NCT03518476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive multi-disciplinary education program on tobacco treatment for pharmacists
Description: Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
Study: NCT03595202

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
Study: NCT01496157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFBC
Description: A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
Study: NCT02055625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
Study: NCT03371563

Intervention type: DRUG
Intervention: Antibiotics
Description: Patients were treated with antibiotics for Lyme disease.

Intervention type: DRUG
Intervention: Antibiotics
Description: Patients were treated with antibiotics for Lyme disease.

Intervention type: DRUG
Intervention: Antibiotics
Description: Patients were treated with antibiotics for Lyme disease.

Intervention type: OTHER
Intervention: no intervention
Description: controls were not given antibiotics